Jay A. Fleischman, MD

Jay A. Fleischman, MD

Retina & Laser Consultants LLC
34 Marconi Avenue
Suite 100
Bronx, NY 10461
United States map

(914) 315-5111 office
(518) 776-1791 fax

Professional Affiliations

Academic Appointments
  • Associate Professor, Albert Einstein College of Medicine
Hospital Appointments
  • Montefiore Medical Center, Bronx, New York
  • Stamford Hospital, Stamford, CT

Education and Training

Ophthalmology residency
Wilmer Eye Institute, Johns Hopkins, Baltimore, Md
Retinal fellowship
Medical College of Wisconsin, Milwaukee
Additional fellowship
Johns Hopkins Medical Institutions, Johns Hopkins School of Medicine, Baltimore, Md
Medical School
Columbia University Physicians and Surgeons, New York, NY
Columbia University Engineering, New York, NY


Dr. Jay Fleischman was a systems analyst/programmer at New York’s NASA Goddard Institute for Space Studies while he completed his applied math/computer engineering and then medical degrees at Columbia University. He completed his ophthalmology training at the Wilmer Institute, Johns Hopkins and his retina specialty training at the Medical College of Wisconsin. In 1980, Jay became the Director of Retina at the Bethesda Eye Institute, St. Louis University and then served as Director at Montefiore Hospital, Albert Einstein College of Medicine to New York in 1988. In 2000 he went into private practice and still serves as a Clinical Associate Professor.

Since 1984, he has lectured and taught surgery around the world through Project ORBIS (the Flying Eye Hospital), has authored many papers, and holds several patents, the latest of which is a device that will help restore vision to patients with macula degeneration, the leading cause of vision loss after age 55. Of the many surgical devices Jay has invented, the laser endophotocoagulator has become an indispensible tool and a worldwide “standard of care” for advanced surgical retina cases. An expert in diabetes treatment and its complications, in particular diabetic retinopathy, he served as an investigator in The Diabetes Control and Complications Trial (DCCT), a landmark medical study conducted by the US National Institute of Diabetes and Digestive and Kidney Diseases.

Jay has consulted for many companies including HGM, Alcon and Mentor and served as an advisor for Dauphin Capital Management, NGN Capital Management and Pfizer. He now serves as a healthcare advisor to CRT Capital.

As a member of Glytec Systems Board of Directors he has helped develop FDA-cleared insulin and glucose dosing software for the outpatient management of diabetes as well as hospital based glycemic management algorithms that replace paper protocols and almost entirely eliminate hypoglycemic events. Jay also serves as a current member of the FDA medical device panel.